Literature DB >> 11535519

Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.

J C Moore1, C P Hayward, T E Warkentin, J G Kelton.   

Abstract

Recent studies investigating thrombotic thrombocytopenic purpura (TTP) have implicated abnormal plasma von Willebrand factor (vWF)-cleaving metalloprotease activity in this disorder. It has been proposed that a metalloprotease cleaves unusually large (UL) multimers of vWF, which enter the circulation from the endothelium. Abnormal metalloprotease activity could result in ULvWF, which could participate in TTP. However, the diagnostic specificity of abnormalities in the plasma metalloprotease activity has not been established. A prospective study of vWF protease activity was performed using samples from 20 healthy controls, 20 patients with acute TTP, 20 patients with immune idiopathic thrombocytopenic purpura (ITP), 10 patients with disseminated intravascular thrombocytopenia (DIC), 10 patients with systemic lupus erythematosus (SLE,) and 5 thrombocytopenic patients with leukemia. Studies were performed blinded to the diagnosis. Samples from hospitalized patients with normal platelet counts were also tested. The vWF digests and multimer analysis were done using previously described methods. Six laboratory personnel independently scored each of the multimer gels. Reduced protease activity was observed in 9 of 20 patients with TTP. Reduced activity was also observed in 6 of 20 patients with ITP, 6 of 10 patients with DIC, 5 of 10 patients with SLE, 1 of 5 patients with leukemia, 2 of 20 healthy controls, and 3 of 25 hospitalized patients. This study indicates that abnormalities of vWF protease activity are not restricted to patients with the diagnosis of TTP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535519     DOI: 10.1182/blood.v98.6.1842

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Lucio Lo Coco; Alessandra Malato; Rosa Di Trapani; Giorgia Saccullo; Giuseppina Pizzo; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.

Authors:  Rena Morita; Satoshi Hashino; Shinichi Shirai; Noriaki Fujita; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Masahiro Asaka
Journal:  Int J Hematol       Date:  2008-07-19       Impact factor: 2.490

Review 3.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

4.  IL-1β down-regulates ADAMTS-13 mRNA expression in cells of the central nervous system.

Authors:  G Alkistis Frentzou; Claire Bradford; Kirsty A Harkness; Gail Haddock; M Nicola Woodroofe; Alison K Cross
Journal:  J Mol Neurosci       Date:  2011-07-06       Impact factor: 3.444

Review 5.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 6.  Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients.

Authors:  Yasuko O Erickson; Noelle I Samia; Bruce Bedell; Kenneth D Friedman; Bonnie S Atkinson; Thomas J Raife
Journal:  J Clin Apher       Date:  2009       Impact factor: 2.821

8.  A rare case of thrombotic microangiopathy triggered by acute pancreatitis.

Authors:  Kevin Singh; Ahmed Jamal Nadeem; Behzad Doratotaj
Journal:  BMJ Case Rep       Date:  2017-05-15

9.  Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.

Authors:  Yoshiaki Chinen; Junya Kuroda; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Miki Kiyota; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Yosuke Matsumoto; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2013-03-14       Impact factor: 2.490

10.  Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.

Authors:  Trung C Nguyen; Yong Y Han; Joseph E Kiss; Mark W Hall; Andrea Cortese Hassett; Ron Jaffe; Richard A Orr; Janine Janosky; Joseph A Carcillo
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.